Wednesday, November 4, 2026
Healthcare and Medical Costs

A Déjà Vu Moment for Women’s Health Research: Past Shortcomings and New Pathways Forward at the NIH

Layla Zulfa
Font Size:
FB X WA TG

The ongoing push to reform and revitalize women’s health research in the United States has reached a critical juncture, drawing intense scrutiny from public health experts, policymakers, and scientific institutions. Writing in a recent commentary published in the scientific journal Nature, Alina Salganicoff, a leading health policy expert with KFF, explores the historical trajectory of federal efforts aimed at advancing women’s health. Salganicoff examines how past initiatives launched during previous U.S. administrations frequently failed to deliver on their grand promises, falling short of creating the systematic, lasting changes required to address deep-seated disparities in medical research.

Against this historical backdrop of recurring inertia, Salganicoff highlights the critical recommendations put forward by a congressionally mandated committee of the National Academies of Sciences, Engineering, and Medicine (NASEM). Having co-chaired this distinguished committee, Salganicoff offers a unique perspective on the structural, financial, and cultural reforms necessary to finally transform how the National Institutes of Health (NIH) approaches and prioritizes women’s health research. The commentary serves as both a cautionary tale about past political and institutional failures and a pragmatic roadmap for future progress.

The discussion surrounding the federal government’s commitment to women’s health is characterized by a persistent cycle of high-profile announcements followed by under-resourced implementation. Over the past several decades, various presidential administrations have pledged to correct the historical exclusion of women from major clinical trials and to boost funding for conditions that disproportionately or differently affect women. However, these well-intentioned declarations have routinely encountered institutional resistance, shifting political priorities, and a lack of binding accountability mechanisms within federal research agencies.

Salganicoff’s analysis in Nature underscores how these previous initiatives often lacked the sustained momentum needed to alter the broader medical research landscape fundamentally. While individual programs or specific funding surges occasionally yielded notable breakthroughs, they failed to institutionalize a comprehensive approach to sex and gender differences across all biomedical research domains. Consequently, critical gaps in knowledge regarding conditions ranging from cardiovascular disease and autoimmune disorders to neurological conditions and reproductive health continue to persist. This repeating cycle of enthusiasm followed by stagnation has left many researchers and advocates with a profound sense of déjà vu, recognizing that incremental tweaks to the existing system are no longer sufficient.

To break this historical pattern, the NASEM committee, co-chaired by Salganicoff, undertook a comprehensive evaluation of the NIH’s organizational structures and research priorities. Congress mandated the study to provide an objective, evidence-based assessment of how federal funding and institutional policies could be modernized to better serve the health needs of women across their lifespans. The committee’s final report outlines a series of targeted recommendations designed to embed accountability, transparency, and rigorous scientific standards into the very fabric of the nation’s premier medical research agency.

Central to the NASEM committee’s recommendations is the need for a fundamental shift in how the NIH designs, oversees, and evaluates research involving sex as a biological variable. Although the NIH implemented policies in the past requiring grantees to include women in clinical research, compliance and enforcement have historically been uneven. The committee calls for stronger oversight mechanisms to ensure that researchers not only recruit diverse cohorts of women but also disaggregate and analyze data by sex and gender to uncover critical differences in disease presentation, progression, and treatment response.

Furthermore, the committee’s findings address the persistent underfunding of conditions that exclusively, predominantly, or differently affect women. For generations, medical research has operated on a male default model, where findings from male animals and human subjects were generalized to the entire population, often with detrimental consequences for women’s healthcare outcomes. The NASEM recommendations emphasize the necessity of dedicated, sustained funding streams that protect women’s health research from the whims of shifting political agendas or budgetary fluctuations within the federal government. By establishing institutional permanence and clear performance benchmarks, the proposed reforms aim to ensure that women’s health is treated as a core component of mainstream biomedical science rather than a marginalized specialty.

The broader implications of these recommendations extend far beyond the administrative halls of the NIH, directly touching upon the ways health information is generated, communicated, and utilized by the public. As patients increasingly turn to digital platforms and online resources to navigate complex medical decisions, the availability of accurate, sex-specific health data becomes even more vital. Ensuring that clinical research robustly reflects the realities of women’s bodies directly enhances the quality of guidance available on critical topics ranging from reproductive care and fertility treatments to broader preventative health measures.

Discussions surrounding women’s health policy and federal budget allocations remain deeply intertwined with broader conversations happening across the Department of Health and Human Services (HHS) and Capitol Hill. As policymakers weigh the NASEM committee’s proposals, the scientific community faces a pivotal choice: continue with the cyclical pattern of episodic attention that has characterized the field for decades, or embrace systemic structural reform that ensures lasting equity in medical research. Through her analysis in Nature, Salganicoff challenges federal leaders to heed the lessons of history and seize the opportunity to build a more inclusive, rigorous, and responsive national research infrastructure.

No comments yet. Be the first to join the conversation!

Join the Discussion

Your email address will not be published. Required fields are marked *

Featured Articles